Pfizer announced positive topline results from pivotal trial of Covid-19 vaccine for children Pfizer Inc. and BioNTech SE, on Monday, September 20, announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older.
